MAYZENT® (siponimod) is a sphingosine 1-phosphate (S1P) receptor modulator and is for oral use.
Tablets: 0.25 mg, 1 mg, and 2 mg
"• Assessments are required prior to initiating MAYZENT.
• Titration is required for treatment initiation.
• The recommended maintenance dosage is 2 mg.
• The recommended maintenance dosage in patients with a CYP2C9*1/*3 or *2/*3 genotype is 1 mg.
• Administer tablets whole; do not split, crush, or chew.
• First-dose monitoring is recommended for patients with sinus bradycardia, first- or second-degree [Mobitz type I] atrioventricular (AV) block, or a history of myocardial infarction or heart failure."
Siponimod is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.